factually
Index/Topics/Anti-amyloid monoclonal antibodies

Anti-amyloid monoclonal antibodies

Discussion of anti-amyloid monoclonal antibodies and their association with ARIA

Fact-Checks

2 results
Jan 15, 2026

What are the rates and clinical consequences of ARIA in real‑world use of lecanemab and donanemab?

Real‑world reports and pooled analyses show that amyloid‑related imaging abnormalities (ARIA) are substantially more common with anti‑amyloid monoclonal antibodies than with placebo, and that lecanema...

Jan 12, 2026

How do anti‑amyloid monoclonal antibodies differ in mechanism, efficacy, and safety (lecanemab vs donanemab vs aducanumab)?

Anti‑amyloid monoclonal antibodies differ in what forms of Aβ they bind, how much they lower brain amyloid and downstream biomarkers, and in clinical benefit versus risk balance: lecanemab targets sol...